Looking at this filing, I can see it's a Form 10-Q for Evolus, Inc. for the quarterly period ended September 30, 2026, filed November 4, 2026. The ticker is EOLS on the Nasdaq Global Market. The filing content provided is primarily the cover page, table of contents, forward-looking statements boilerplate, and the summary of risk factors. Let me assess the substantive disclosure content excluding boilerplate and cautionary language. The substantive content includes: share count (66,188,366 shares as of October 30, 2026), accelerated filer status, the company's specific risk factor summaries mentioning Symatese S.A.S., Evolysse product line, tariff risks, settlement agreements, and specific business characteristics. This exceeds 150 words of substantive content.

Evolus, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 4, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Share count: As of October 30, 2026, 66,188,366 shares of common stock, par value $0.00001, were outstanding, according to the filing.
  • Filer status: The company is classified as an accelerated filer, not a large accelerated filer, smaller reporting company, or emerging growth company, the filing states.
  • Supplier reliance disclosed: The filing identifies reliance on Symatese S.A.S. for regulatory approval of the Evolysse product line as a principal risk.
  • Trade policy risk flagged: The company disclosed that tariffs and regulatory actions on imports "may have a material adverse impact" on results of operations and financial condition.
  • Settlement agreement risk noted: The filing flags potential risk if the company or its counterparties do not comply with the terms of its settlement agreements.
  • Ongoing losses acknowledged: The company disclosed that it "has incurred significant losses since our inception" and may continue to incur losses.

Evolus Quarterly Filing: Business Risks and Share Position for Period Ended September 30, 2026

Evolus, Inc. (NASDAQ:EOLS), a Delaware-incorporated company headquartered at 520 Newport Center Drive, Suite 1200, Newport Beach, California, submitted its quarterly report covering the three-month period ended September 30, 2026. The filing confirms the company operates as an accelerated filer under SEC definitions and is not classified as a shell company.

According to the filing, the company's products face competitive pressures in the aesthetic practitioner market and are subject to consumer discretionary spending patterns. The company specifically noted that its products "rely on consumer discretionary spending and the purchasing decisions of our customers, both of which are sensitive to global economic conditions, including the imposition of tariffs, or changes in consumer or customer sentiment." The filing identifies the Evolysse product line, for which Symatese S.A.S. is cited as a key regulatory approval partner, as a source of potential business risk if approvals are not obtained or maintained on the company's estimated time frame.

The filing also discloses that the company may require additional financing to fund future operations or corporate development activities, and that a failure to secure capital "on acceptable terms, or at all, could force us to delay, limit, reduce or terminate" its operations. These statements are the company's own and are subject to its cautionary language regarding forward-looking statements. The company confirmed it has filed all required Exchange Act reports during the preceding 12 months and has submitted all required Interactive Data Files electronically.

What Was Disclosed

Evolus filed its September 30, 2026 quarterly report disclosing 66,188,366 shares outstanding as of October 30, 2026, its accelerated filer classification, reliance on Symatese S.A.S. for the Evolysse product line, ongoing losses since inception, and risks related to tariffs, competition, and settlement agreements.